3.42 General discussion 205 48. Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol 2013;42:1012–1014. doi:10.1093/ije/dys223. 49. Sharma A, Zhao X, Hammill BG, Hernandez AF, Fonarow GC, Felker GM, et al. Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. Circ Heart Fail 2018;11:e004646. doi:10.1161/CIRCHEARTFAILURE.117.004646. 50. Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur J Prev Cardiol 2020;27:27–34. doi:10.1177/2047487320960288. 51. Tedeschi A, Agostoni P, Pezzuto B, Corra’ U, Scrutinio D, La Gioia R, et al. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. Eur J Prev Cardiol 2020;27:35–45. doi:10.1177/2047487320957793. 52. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet 2010;375:2073–2081. doi:10.1016/S0140-6736(10)60674-5. 53. Schrage B, Rübsamen N, Ojeda FM, Thorand B, Peters A, Koenig W, et al. Association of iron deficiency with incident cardiovascular diseases and mortality in the general population. ESC Heart Failure 2021;8:4584–4592. doi:10.1002/ehf2.13589. 54. Lanser L, Fuchs D, Scharnagl H, Grammer T, Kleber ME, März W, et al. Anemia of Chronic Disease in Patients With Cardiovascular Disease. Frontiers in Cardiovascular Medicine 2021;8. 55. Usman MS, Van Spall HGC, Greene SJ, Pandey A, McGuire DK, Ali ZA, et al. The need for increased pragmatism in cardiovascular clinical trials. Nat Rev Cardiol 2022:1–14. doi:10.1038/s41569-02200705-w. 56. U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. Silver Spring, MD: Center for Drug Evaluation and Research; 2020. 57. Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, et al. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiol 2020;5:1–8. doi:10.1001/jamacardio.2020.0640. 58. Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, et al. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology 2022;79:504–510. doi:10.1016/j.jacc.2021.11.033. 59. Packer M, Metra M. Guideline-directed medical therapy for heart failure does not exist: a nonjudgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure 2020;22:1759– 1767. doi:10.1002/ejhf.1857. 60. Ozaki AF, Krumholz HM, Mody FV, Jackevicius CA. National Trends in the Use of Sacubitril/Valsartan. Journal of Cardiac Failure 2021;27:839–847. doi:10.1016/j.cardfail.2021.05.015. 61. Innovative Medicines Initiative. BigData@Heart. IMI Innovative Medicines Initiative 2021. http://www.imi.europa.eu/projects-results/project-factsheets/bigdataheart (accessed September 7, 2021). 62. European Federation of Pharmaceutical Industries and Associations (EFPIA). Innovative Medicines Initiative (IMI) 2022. https://www.efpia.eu/about-medicines/development-of-medicines/publicprivate-partnerships/ (accessed July 5, 2022). 63. Anker S, Asselbergs FW, Brobert G, Vardas P, Grobbee DE, Cronin M. Big Data in Cardiovascular Disease. Eur Heart J 2017;38:1863–1865. doi:10.1093/eurheartj/ehx283. 64. MacDonald MR, Tay WT, Teng TK, Anand I, Ling LH, Yap J, et al. Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐
RkJQdWJsaXNoZXIy MjY0ODMw